Physician profile
Omar B Nesheiwat
NPI 1730683350
$10,341.15
in general payments reported to CMS, 2019-2025
24 companies · $5,924 in 2025
The $5,924 reported for 2025 was more than what 89% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,568 · 2023: $737 · 2024: $2,112 · 2025: $5,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,350 · Consulting Fee: $3,300 · Travel and Lodging: $123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,349.93 |
| Consulting Fee | $3,300.00 |
| Travel and Lodging | $123.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,306.06 | 2023-2025 | |
| Neuropace, INC. | $1,427.67 | 2022 | |
| Ucb, INC. | $922.68 | 2023-2025 | Fintepla, Briviact, Rystiggo |
| Neurelis, INC. | $852.88 | 2023-2025 | Valtoco |
| Pfizer INC. | $460.54 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $410.78 | 2023-2025 | Nuplazid |
| Sk Life Science, INC. | $382.51 | 2023-2025 | |
| Merz Pharmaceuticals, LLC | $267.87 | 2023-2025 | Xeomin, Inbrija, Ampyra |
| Penumbra, INC. | $240.45 | 2024-2025 | Penumbra System |
| Eisai INC. | $162.58 | 2025 | |
| Jazz Pharmaceuticals INC. | $142.50 | 2022-2025 | Epidiolex |
| Xtant Medical INC | $120.65 | 2024 | |
| Vanda Pharmaceuticals INC. | $99.62 | 2024-2025 | Ponvory |
| Lilly USA, LLC | $91.98 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Astrazeneca Pharmaceuticals Lp | $87.17 | 2024-2025 | Wainua |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $84.96 | 2024-2025 | Austedo Xr, Austedo Xr |
| Grifols USA, LLC | $84.75 | 2024 | Gamunex-C |
| Microtransponder, INC. | $57.72 | 2023-2024 | |
| Neurocrine Biosciences, INC. | $35.63 | 2025 | |
| Janssen Pharmaceuticals, INC | $27.50 | 2023 | Xarelto |
| Allergan, INC. | $24.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $23.20 | 2024 | Onpattro |
| Forte Bio-Pharma LLC | $13.61 | 2025 | Tanlor |
| Lundbeck LLC | $13.49 | 2025 | Vyepti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omar Nesheiwat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.